Abstract | OBJECTIVE: METHODS: RESULTS: After 14 weeks of TNF alpha blockade treatment, there was a significant increase in levels of total cholesterol (5.08+/-1.20 vs. 4.73+/-1.12 mmol/l; p=0.01) and HDL-cholesterol (1.61+/-0.47 vs. 1.47+/-0.35 mmol/l; p=0.008), but no resulting change in the atherogenic index (3.43+/-1.13 vs. 3.35+/-0.93; p=0.87). There was also no change in concentrations of triglycerides (1.33+/-1.22 vs. 1.27+/-0.98 mmol/l; p=0.794) and LDL-cholesterol (3.15+/-0.99 vs. 2.91+/-0.93 mmol/l; p=0.24). TNF alpha inhibitor treatment was followed by a significant improvement in all disease activity parameters: VAS pain or VAS disease activity, BASDAI or BASFI and systemic inflammation. Sub-group analysis showed that monoclonal antibodies increased total and LDL-cholesterol levels but did not change the atherogenic index. Conversely, 14 weeks of etanercept treatment was followed by no change in lipid profile. CONCLUSION:
TNF alpha inhibitors may be successful in reducing cardiovascular risk in AS, as in RA, but not by affecting lipid profile. However, there is insufficient documented evidence, and long-term investigations are needed to define the possible protective mechanisms of TNFalpha inhibitor treatment in spondylarthropathies.
|
Authors | Sylvain Mathieu, Jean-Jacques Dubost, Anne Tournadre, Sandrine Malochet-Guinamand, Jean-Michel Ristori, Martin Soubrier |
Journal | Joint bone spine
(Joint Bone Spine)
Vol. 77
Issue 1
Pg. 50-2
(Jan 2010)
ISSN: 1778-7254 [Electronic] France |
PMID | 20022785
(Publication Type: Journal Article)
|
Copyright | Copyright 2009 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved. |
Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Lipids
- Receptors, Tumor Necrosis Factor
- Triglycerides
- Tumor Necrosis Factor-alpha
- Cholesterol
- Etanercept
|
Topics |
- Adult
- Antirheumatic Agents
(therapeutic use)
- Cholesterol
(blood)
- Etanercept
- Humans
- Immunoglobulin G
(therapeutic use)
- Lipid Metabolism
(drug effects, physiology)
- Lipids
(blood)
- Male
- Pain
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Severity of Illness Index
- Spondylitis, Ankylosing
(blood, drug therapy, physiopathology)
- Triglycerides
(blood)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, blood)
|